Tempus AI, Inc. (TEM)

NASDAQ: TEM · Real-Time Price · USD
54.07
-2.99 (-5.24%)
At close: May 5, 2025, 4:00 PM
53.40
-0.67 (-1.24%)
After-hours: May 5, 2025, 7:45 PM EDT
-5.24%
Market Cap 9.36B
Revenue (ttm) 693.40M
Net Income (ttm) -746.33M
Shares Out 173.03M
EPS (ttm) -6.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,202,402
Open 55.50
Previous Close 57.06
Day's Range 52.88 - 55.55
52-Week Range 22.89 - 91.45
Beta n/a
Analysts Buy
Price Target 61.10 (+13.0%)
Earnings Date May 6, 2025

About TEM

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 2,400
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.

Financial numbers in USD Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $61.1, which is an increase of 13.00% from the latest price.

Price Target
$61.1
(13.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-po...

17 hours ago - Business Wire

Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its su...

4 days ago - Business Wire

Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Anal...

6 days ago - Business Wire

Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-foc...

7 days ago - Business Wire

Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including on...

10 days ago - Business Wire

Tempus to Report First Quarter 2025 Financial Results on May 6

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on...

11 days ago - Business Wire

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collabora...

Other symbols: AZN
12 days ago - Business Wire

Tempus AI: Cooldown Arrived (Rating Upgrade)

Tempus AI is trading near yearly lows despite strong growth prospects, driven by the Ambry Genetics acquisition and robust organic growth. The company has innovative AI diagnostic services, including ...

13 days ago - Seeking Alpha

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Adviso...

17 days ago - Business Wire

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN...

Other symbols: ILMN
20 days ago - PRNewsWire

Is it safe to buy the Tempus AI stock dip now?

Tempus AI stock price remains in a deep bear market as investors worry that the hype that drove it to a record high was ending. The TEM stock initially peaked at $91.40 in February, and has now plunge...

26 days ago - Invezz

Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exh...

5 weeks ago - Business Wire

Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual...

5 weeks ago - Business Wire

Tempus AI: The Investment Opportunity Of A Decade, Strong Buy

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter and strong revenue growth projected for FY25. Q4FY24 saw record revenues, driven by a 35.8% YoY growth...

6 weeks ago - Seeking Alpha

Tempus Announces Acquisition of Deep 6 AI

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a le...

7 weeks ago - Business Wire

Tempus AI: Buying The Dip After 2025 Guidance Raise

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results, presenting a buying opportunity due to raised 2025 revenue guidance. The company, a leader in healthcar...

2 months ago - Seeking Alpha

Tempus AI Earnings: A Promising Business, But There Are Risks

Tempus AI's core business growth is slowing, raising doubts about its AI-led narrative and long-term sustainable growth rates. Despite impressive revenue growth projections, Tempus AI remains free cas...

2 months ago - Seeking Alpha

Tempus AI, Inc. (TEM) Q4 2024 Earnings Call Transcript

Tempus AI, Inc. (NASDAQ:TEM) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Liz Krutoholow - Investor Relations Eric Lefkofsky - Founder & Chief Executive Officer ...

2 months ago - Seeking Alpha

Tempus Reports Fourth Quarter and Full Year 2024 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

2 months ago - Business Wire

Tempus AI Gears Up For Q4 Earnings After 101% YTD Surge

Tempus AI Inc TEM will be reporting its fourth-quarter earnings on Monday. Wall Street expects a loss of 20 cents per share and $203.12 million in revenues as the company reports after market hours.

2 months ago - Benzinga

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equ...

Other symbols: ARDXGERNMRNAPSNL
2 months ago - Seeking Alpha

Tempus to Present at TD Cowen's 45th Annual Health Care Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health...

2 months ago - Business Wire

Ares Management Upsizes Tempus Debt Facilities to $560 Million

NEW YORK--(BUSINESS WIRE)--Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent...

Other symbols: ARES
2 months ago - Business Wire

Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Recently, they've made some interesting moves l...

2 months ago - Seeking Alpha

Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technolo...

2 months ago - Business Wire